References
- Darmon M, Guichard I, Vincent F, Schlemmer B, Azoulay É. Prognostic significance of acute renal injury in acute tumor lysis syndrome. Leuk Lymphoma 2009; 51:221–227.
- Pumo V, Sciacca D, Malaguarnera M. Tumor lysis syndrome in elderly. Crit Rev Oncol Hematol 2007;64:31–42.
- Magrath I. Lessons from clinical trials in African Burkitt lymphoma. Curr Opin Oncol 2009;21:462–468.
- Kabisch H, Niggemann B, Winkler K. [Extreme hyperphosphatemia with hypocalcemia within the scope of cell lysis syndrome in a child with T-ALL]. Onkologie 1989;12:64–68.
- Potter JL, Silvidi AA. Xanthine lithiasis, nephrocalcinosis, and renal failure in a leukemia patient treated with allopurinol. Clin Chem 1987;33:2314–2316.
- Pession A, Melchionda F, Castellini C. Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase). Biologics 2008;2:129–141.
- Campara M, Shord SS, Haaf CM. Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach. J Clin Pharm Ther 2009;34:207–213.
- Cheson BD. Etiology and management of tumor lysis syndrome in patients with chronic lymphocytic leukemia. Clin Adv Hematol Oncol 2009;7:263–271.
- Al-Kali A, Farooq S, Tfayli A. Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia. J Clin Pharm Ther 2009;34:607–610.
- Jeha S, Kantarjian H, Irwin D, et al Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia 2005;19:34–38.
- Annemans L, Moeremans K, Lamotte M, et al Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients. Support Care Cancer 2003;11:249–257.